This is an academic paper that summarizes the evidence supporting medications for opioid use disorder (MOUD). It provides an overview of the pharmacology of MOUD, and discusses clinical indications for each form of MOUD.

This is an academic paper that provides a synopsis of the evidence for buprenorphine in treating opioid use disorder (OUD). The study concludes that buprenorphine is associated with improved outcomes compared with placebo for individuals and pregnant women with OUD and that buprenorphine treatment should be considered for inclusion as a covered benefit.

This is an academic paper that provides a synopsis of the evidence for methadone as a medication for opioid use disorder (MOUD). The study concludes that methadone is associated with improved outcomes for individuals and pregnant women with opioid use disorders, and that methadone should be a covered service available to all individuals.

This is a report from SAMHSA for a wide range of stakeholders (healthcare professionals, policymakers, patients, and families) that gives an overview of the three FDA-approved medications used to treat opioid use disorder (OUD) as well as other strategies and services needed to support recovery for people with OUD. Resources are provided at the end of this document. An executive summary of the report can be found here. 

This is an interactive mapping tool that gives an overview of what types of medications for opioid use disorder are provided in state prisons (methadone, buprenorphine, and/or naltrexone) at the state level along with supporting documents for this data. 

This is a consensus study report of the National Academies of Sciences, Engineering, and Medicine put together by a committee of experts in the field. It summarizes the evidence on medications for opioid use disorder (MOUD), discusses the use of and evidence for these medications in different populations and settings, and identifies barriers to implementing MOUD. 

This report from SAMHSA provides an updated overview of three Food and Drug Administration-approved medications for opioid use disorder treatment—methadone, naltrexone, and buprenorphine—and other strategies and services needed to support people in treatment. It is targeted towards healthcare and addiction professionals, policymakers, patients, and their families. 

This is an academic paper that describes the collaboration between a multidisciplinary team of university, state and federal agency, and community experts to create a unified database linking controlled substance prescribing, overdose, and treatment for opioid use disorder in Connecticut that can better-inform interventions across the state. 

This report examines the current federal regulatory and legal landscape around the provision of and access to methadone for the treatment of OUD. It explores potential policy changes to address federal, state, and local barriers to the provision of methadone treatment and consider opportunities for implementing office-based methadone treatment.

This is a report from the Alliance for Addiction Payment Reform, a group advocating for employing a chronic disease model of treatment for substance use disorder, that gives an overview of the availability of digital technology options to improve treatment outcomes, such as telehealth, digital apps, virtual recovery supports, and wearables and monitoring devices. 

This is an academic paper that is a quality improvement study in which the authors investigated whether medications used to treat opioid use disorder such as buprenorphine can be effectively provided to individuals living in rural areas via telemedicine in a mobile treatment unit. Findings suggest that the combination of telemedicine and mobile services is a unique approach to extend access to medications for opioid use disorder to rural areas 

This is a guide from the National Association of County and City Health Officials (NACCHO) which provides strategies for rural communities to mobilize community partnerships for public health programming, including local examples and lessons learned.